Interactive Attention Training Technology To Enhance Cognitive Skills In Early Life
Funder
National Health and Medical Research Council
Funding Amount
$759,680.00
Summary
Over 30,000 Australian children enter school with attention difficulties each year. We have established a suite of tasks to train attention based on over 20 years of research into neurodevelopmental disorders and attention. These are delivered on tablets in the form of a game known as TALI Train. We now aim to show TALI can improve attention in children with acquired brain injuries and typically developing children for commercialisation to a broad market.
Epilepsy affects over 65 million people worldwide and approximately 30% of sufferers do not respond to drugs. For these people, electrodes are placed in the brain to monitor brain activity and stop the initiation or progression of seizures. However, state-of-the-art devices require risky open-brain surgery. In this project, we are developing a Stentrode Neuro-Stimulator (SNS) for the treatment of drug-resistant epilepsy without the need for open-brain surgery.
This proposal seeks to develop a novel non-invasive method of measuring intra-cranial pressure, an important diagnostic parameter in many form of brain injury or neural disease. It works by quantitative video analysis of the pulsation of the major vein in the eye during induced rises in eye pressure. Many years of study by our group have determined the relationship between vein pulsation pressure and intra-cranial pressure, and this information is used to produce an accurate measurement of intra ....This proposal seeks to develop a novel non-invasive method of measuring intra-cranial pressure, an important diagnostic parameter in many form of brain injury or neural disease. It works by quantitative video analysis of the pulsation of the major vein in the eye during induced rises in eye pressure. Many years of study by our group have determined the relationship between vein pulsation pressure and intra-cranial pressure, and this information is used to produce an accurate measurement of intra-cranial pressure without the need for surgery.Read moreRead less
Application Of Sutureless Technology 'SurgiLux' For Dura Mater Repair: A Proof Of Concept Study
Funder
National Health and Medical Research Council
Funding Amount
$213,125.00
Summary
A unique technology that combines biomaterials and lasers to effectively close and seal wounds could replace sutures in delicate surgery close to the brain. Wound closure in the cranium is still reliant upon sutures or 'stitches' and these have complications; a major one being leakage of cerebro spinal fluid (CSF). The application of 'SurgiLux' technology will both close and seal these wounds quickly and easily, with significant health and economic benefits.
Development Of Microscope-in-a-needle Devices For Improved Clinical Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$327,746.00
Summary
We have developed a new high-resolution optical imaging technology. The unique aspect of our research has been to redesign the imaging probe, miniaturising it to a few hundred microns in diameter, and encase it in a hypodermic needle – a ‘microscope-in-a-needle’. We are developing specific imaging probes to aid in the assessment of lung disease; the diagnosis of liver disease; and integrated into a brain biopsy needle to enable safer brain biopsies.
Electrical Stimulation Of The Brain For Restoring Vision
Funder
National Health and Medical Research Council
Funding Amount
$1,555,864.00
Summary
This project is focused on the clinical demonstration of the Monash Vision Group’s ‘Gennaris’ cortical prosthesis or bionic eye. The clinical work will demonstrate the use of the Gennaris as a viable medical device that provides useful vision to people with adult-onset profound vision loss in their everyday living environments. This will place MVG in a position to attract funding from investors or commercial partners to perform multi-site clinical trials and obtain regulatory approval.
Novel Therapy For Enhancing Organ Maturation In Pre-term Babies
Funder
National Health and Medical Research Council
Funding Amount
$694,323.00
Summary
This project is developing a factor to enhance organ maturation and repair that may provide a new therapy for premature babies and fetuses with birth defects. This exciting new finding allows for the development of treatments of underdeveloped organs, in particular the lungs of premature and growth restricted babies. We are also trialing this factor in unborn babies with defects to the kidneys and lungs of which there is currently no cure.
Sensitizing Tumours To Immunotherapy: Development Of An RNA-based Therapeutic For Pancreatic Adenocarcinoma That Targets The Immunosuppressive Tumour Microenvironment.
Funder
National Health and Medical Research Council
Funding Amount
$192,347.00
Summary
The blood vessels of tumours are highly abnormal resulting in leakiness and hypoxia within the microenvironment. These abnormalities contribute both to the pathology and also to resistance to treatment. We have developed a new drug that is able to inhibit vascular leak, better the response to therapies and improve disease outcome. This work will generate essential data for the development of this drug towards Clinical Trials through interaction with International Pharma.
Development Of A Safe Live Genetically Attenuated Blood Stage Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$822,191.00
Summary
Malaria presents an enormous global health problem, and also has a significant impact on social and economic development in countries where the disease is endemic. Our project will produce a live genetically-modified vaccine against Plasmodium falciparum, the parasite that causes the form of malaria mostly deadly to humans. Our development plan will include the first ever clinical trials of a malaria vaccine of this kind and will look at vaccine safety and effectiveness.
Optimisation Of A Potent And Fast Acting Antimalarial Class That Is Orally Efficacious In Vivo
Funder
National Health and Medical Research Council
Funding Amount
$683,916.00
Summary
Malaria is a devastating disease that results in 600 000 deaths annually. Current therapeutics used to combat malaria have a limited duration of use in the clinic due to the onset of resistance. We have identified a highly active antimalarial series that we propose to further develop to meet the prerequisites required for partnership with the Medicines for Malaria Venture (MMV) for progression into the clinic.